ArticleScientific reports2024

Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.

Agampodi Danushi Mendis Gunasekara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.